Adventrx CoFactor To Begin Phase III In Q2 Following SPA Agreement With FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adventrx' Phase III trial of CoFactor will evaluate the folate-based biomodulator's ability to improve the efficacy and safety of the chemotherapeutic agent 5-fluorouracil in patients with metastatic colorectal cancer